Numab

At Numab, we build next-generation multispecific antibody-based therapeutics designed to tackle inflammation and oncology challenges with a repeatable, plug-and-play discovery approach. Our proprietary platforms - λ-Cap™ and MATCH™ - are described as enabling a rational and reproducible process to rapidly yield clinical candidates, including tailored pharmacokinetic properties and engineering strategies intended to improve potency, stability, effect duration, and safety. Rather than treating drug discovery as a one-off effort, our culture centers on engineering rigor, validated discovery and engineering technologies, and building differentiated programs with clinically validated pathways.

We also operate with strong collaboration in mind. Alongside our in-house pipeline, Numab pursues strategic discovery and development partnerships with pharmaceutical and biotech companies, and we make our discovery engine available to partners seeking antibody-based therapeutics with multiple specificities and readiness for preclinical and process development. On our website and LinkedIn, we emphasize teamwork and a fast-paced, science-driven environment - values that support the sustained advancement of a diversified pipeline in inflammation and immuno-oncology.